Simtriyo clinical data: adolescents
Designed for the many ways ADHD shows up in adolescence
In a clinical trial, adolescents (aged 13 through 17) taking Simtriyo demonstrated improvements in ADHD symptoms. Simtriyo may be an option for patients struggling with a range of ADHD challenges.1-4
Actor portrayal
false
40
24
40
1060px
Adolescent clinical trial design
- Randomized, double-blind, placebo-controlled study of patients aged 13 through 171,2
- Patients were randomized (1:1:1) to receive 140 mg Simtriyo, 280 mg Simtriyo, or placebo once daily for 6 weeks1,2
- Primary endpoint: Change from baseline vs placebo at Week 6 in ADHD-RS-5 symptoms total raw score1,2
- Secondary endpoints: Change from baseline vs placebo in CGI-S-ADHD score and change from baseline vs placebo in the Conners 3 Parent Short Form T-scores (hyperactivity-impulsivity, inattention, defiance/aggression, and executive functioning)2
ADHD-RS-5=ADHD Rating Scale–5; CGI-S-ADHD=Clinical Global Impressions–Severity of Illness–ADHD; LS=least squares.
custom
asymmetric-border-radius,disable-texture
104
72
0
patient-cards
Actor Portrayal
false
Could Simtriyo help patients like Izzy?
Izzy, age 13,‡ was recently diagnosed with ADHD. See how patients like Izzy may be struggling with a range of ADHD challenges.
See challenges
‡Hypothetical patient.
blue
top-left-bottom-right
104
72
72
green
ADDITIONAL CLINICAL DATA IN ADOLESCENTS
Key secondary & exploratory endpoints and open-label extension
button
Learn More
right
full-width
72
24
72
reference
Key secondary & exploratory endpoints: Findings on associated features of ADHD in adolescent patients
Open-label extension study in pediatric patients
ole
104
40
0
Simtriyo: Designed with the patient in mind
See safety and tolerability data in pivotal studies of pediatric patients taking Simtriyo.
See adolescent safety data
blue
See how Simtriyo performs across patient types
green
104
72
0
custom
2.23fr 4.01fr
1
custom
110px
custom
32px
stretch
1060px / 900px / 355px
center
false
96
72
0
default
REFERENCES
- Simtriyo Prescribing Information. Otsuka America Pharmaceutical, Inc. 2026.
- Ward CL, et al. Centanafadine for attention-deficit/hyperactivity disorder in adolescents: a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. Published online July 4, 2025. doi:10.1016/j.jaac.2025.06.023
- Oberdhan D, et al. Efficacy of centanafadine on the Conners 3–Learning Problems Content Scale in pediatric patients with attention-deficit/[br-d]hyperactivity disorder. Poster presented at: Psych Congress 2024; October 29–November 2, 2024; Boston, MA.
- Turkoglu O, et al. Long-term safety and efficacy of centanafadine in children and adolescents with ADHD: results from a phase 3 open-label extension study. Poster presented at: APSARD 2026; January 15-18, 2026; San Diego, CA.
24
24
0
false